Urgent(R) PC and Macroplastique(R) Presentations at American Urological Association 2010 Annual Meeting

MINNEAPOLIS, May 27 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that at the May 28-June 2, 2010 Annual Meeting of the American Urological Association (AUA) in San Francisco, CA, there will be two presentations on Uroplasty's Urgent® PC Neuromodulation System and one on its Macroplastique® urethral bulking agent.

Urgent PC presentations:

• "Percutaneous Tibial Nerve Stimulation (PTNS): A Multi-Center, Randomized, Sham-Controlled Trial for Overactive Bladder Syndrome," presented by Kenneth M. Peters, MD, Beaumont Hospital, Royal Oak, MI.  
• "Long Term Cost Effectiveness of Percutaneous Tibial Nerve Stimulation (PTNS) and Sacral Nerve Stimulation (SNS) for Overactive Bladder (OAB) Treatment," presented by Scott MacDiarmid, MD, Alliance Urology Specialists, Greensboro, NC.

"The efficacy and clinical use of our products will continue to be reinforced through presentations by thought leaders gathering at the 2010 AUA Annual Meeting," said David Kaysen, President and CEO of Uroplasty.  "Dr. Kenneth Peters will present data from the SUmiT Trial, published in the April 2010 edition of THE JOURNAL OF UROLOGY®. This pivotal multi-center study demonstrated that Urgent PC results were statistically significant compared to a placebo treatment. Dr. Scott MacDiarmid's presentation will focus on the clinical and cost effectiveness of the Urgent PC Neuromodulation System. This timely presentation will address comparative effectiveness which is currently foremost in the minds of third-party payers."

Macroplastique presentation:

• "Animal Study Histopathology of the Long Term Durability of Polydimethylsiloxane Injectable Bulking Agent (Macroplastique®) in Urethral Tissues," presented by William Wustenberg, DVM, AlterNetMD Consulting, Farmington, MN.

"Data on the long term durability of Macroplastique will give physicians further information on its clinical application in female stress urinary incontinence," Kaysen said. "We believe urologists will continue to be interested in our products because they provide a minimally invasive and clinically effective treatment solution for their patients. The AUA Annual Meeting will also be the first time that we can publicly discuss with our current and potential customers the January 1, 2011 Category I CPT® Code for percutaneous tibial nerve stimulation (PTNS) delivered via Urgent® PC. Our product is currently the only FDA-cleared PTNS device used to treat the symptoms of Overactive Bladder," concluded Mr. Kaysen.

CPT is a registered trademark of the American Medical Association.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary symptoms often associated with overactive bladder (OAB).  We also offer Macroplastique Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence.  Please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  Further, we cannot assure you that third-party payers will provide or continue to provide coverage and reimbursement for our products, or reimburse the providers an amount sufficient to cover their costs and expenses.  We further cannot assure that reimbursement or other issues will not further impact our future results.

For Further Information:

SOURCE Uroplasty, Inc.